

2007

Pharma **POOL**Lee **DAVIES**

Schering-Plough Appoints  
Director, Global Product  
Communications and  
Advocacy Relations

Schering-Plough, a global science-based healthcare company, has appointed Lee Davies director, global product communications and advocacy relations.

Mr. Davies is responsible for global product communications and advocacy relations programs supporting Schering-Plough's cardiovascular portfolio. He is based at the company's headquarters in Kenilworth, N.J.

Most recently, Mr. Davies was a senior VP with Ogilvy Public Relations Worldwide.

Mr. Davies holds a B.A. in biology and English from Columbia. He has an MBA in marketing management and information systems from the Wharton Graduate School of the University of Pennsylvania.

Dr. Edmund P.  
**HARRIGAN**

Pfizer VP Heads Expanded  
Worldwide Licensing and  
Business Development

Pfizer, New York, has promoted Edmund P. Harrigan, M.D., to senior VP of worldwide licensing and business development.

The group has overall responsibility for co-promotion and licensing agreements, venture capital investments in new technologies, and the acquisition of promising new products and services from outside the company.

A board certified neurologist, Dr. Harrigan has served as senior VP of worldwide regulatory affairs and quality assurance at Pfizer since 2003.

Dr. Harrigan holds a bachelor's degree in chemistry from St. Anselm College, New Hampshire, and a doctorate in medicine from the University of Massachusetts at Worcester, where he also received his medical degree.

Dr. Howard  
**HUTCHINSON**

AstraZeneca Appoints  
Chief Medical Officer

AstraZeneca, an international healthcare company engaged in the research, develop-

ment, manufacture, and marketing of prescription pharmaceuticals and the supply of healthcare services, has appointed Howard Hutchinson, M.D., as chief medical officer. Dr. Hutchinson provides medical oversight of the early- and late-stage portfolio in global drug development and interacts with medical and industry related organizations as AstraZeneca's senior medical representative. He is a Fellow of the American College of Cardiology and an adjunct clinical associate professor of medicine at Thomas Jefferson University Hospital.

Dr. Hutchinson most recently held the position of VP, clinical development, in the cardiovascular/gastrointestinal therapy area at AstraZeneca, Wilmington, Del., and has worked for the company in a progression of clinical roles since 1995.

He obtained a degree in chemistry from Drexel University in 1983, graduating from the Thomas Jefferson University Medical School in 1987. Dr. Hutchinson undertook a postgraduate degree from the cardiology division of the Stanford University School of Medicine in 1995.

Dr. Mark **LONGER**

Napo Appoints VP, Program  
Planning and Management

Mark Longer, Ph.D., has joined Napo, as VP, program planning and management. Napo, South San Francisco, Calif., focuses on the development and commercialization of proprietary pharmaceuticals for the global

WYETH'S CHIEF MEDICAL OFFICER  
NAMED ONE OF AMERICA'S TOP CARDIOLOGISTS

Dr. Gary **STILES**

Gary L. Stiles, M.D., Wyeth Pharmaceuticals' chief medical officer, has been named one of the top cardiologists in America by Consumers' Research Council of America, Washington, D.C.

Dr. Stiles joined Wyeth in January 2004. In his current position he is responsible for clinical research and development and global medical affairs. Dr. Stiles plays a critical role in shaping Wyeth's clinical research strategy to support both the scientific and commercial vision of the company.

Throughout his career, Dr. Stiles has authored more than 150 articles in peer-reviewed scientific journals and other medical publications. He has received numerous research grants and prestigious awards, including the Young Investigator Award

from the American College of Cardiology and the American Heart Association's Louis N. Katz Basic Science Research Prize.

Wyeth, Madison, N.J., is a research-driven pharmaceutical and healthcare products company. The company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The Consumers Research Council of America is a research organization that provides information guides for consumers of professional services throughout the United States.



*Dr. Gary Stiles is  
one of America's  
top cardiologists.*

marketplace in collaboration with local partners.

He is responsible for planning, management, and integration of Napo's ongoing chemistry, manufacturing and controls, and clinical development programs, focusing on Napo's lead product, crofelemer.

Dr. Longer, 49, was most recently senior director, pharmaceutical sciences, at Pfizer Global Research and Development in La Jolla, Calif. He received a B.A. in chemistry from The College of Wooster (Ohio) and a Ph.D. in pharmaceuticals from the University of Wisconsin.

## Daniel B. SOLAND

### ViroPharma Names VP and Chief Commercial Officer

ViroPharma has appointed Daniel B. Soland as VP and chief commercial officer. Mr. Soland oversees the company's commercial infrastructure, including sales and marketing, manufacturing, and commercial and market analysis. ViroPharma, Exton, Pa., is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings.

Mr. Soland joins ViroPharma from his previous post as president of Chiron Vaccines, where he was responsible for managing the vaccine division.

Mr. Soland holds a B.S. in pharmacy from the University of Iowa.

## Biotech POOL

## Dr. Gary C. CUPIT

### President of Enzo Therapeutics Unit Appointed

Enzo Biochem has appointed Gary C. Cupit, Pharm.D., to the newly created position of president of Enzo Therapeutics, New York.

Dr. Cupit, a senior executive with 20 years of experience in the pharmaceutical industry, previously was president and CEO of Sapphire Therapeutics.

Enzo Biochem and its subsidiaries are engaged in the research, development, and manufacture of innovative healthcare products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

Dr. Cupit earned his B.S. in pharmacy from the Medical College of Virginia and his doctor of pharmacy from the Philadelphia College of Pharmacy and Science.

## Thomas FLANAGAN

### Amgen Names Senior VP and Chief Information Officer

Amgen, Thousand Oaks, Calif., a biotechnology company, has appointed Thomas Flanagan as senior VP and chief information officer. He replaces Hassan Dayem, who is retiring.

Mr. Flanagan joined Amgen in June 2004 as VP, information systems, and has been leading Amgen's global enterprise resource planning program since February 2005.

Before joining Amgen, Mr. Flanagan spent eight years at MCI, where he served in a variety of executive capacities, including CIO and senior VP of global service delivery.

## Leonard KANAVY

### Genentech Announces VP Appointment

Leonard Kanavy joins Genentech, South San Francisco, Calif., as VP, commercial operations. Mr. Kanavy is responsible for market planning, forecasting, sales operations, and data acquisition. He oversees commercial training, commercial business processes, thought leader management, and market communications groups.

He joins Genentech from Novartis, where he was most recently VP, commercial operations.

Mr. Kanavy holds a B.S. in management and an MBA from the University of Scranton.

## Dr. Scott MCCALLISTER

### Panacos Appoints Chief Medical Officer

Panacos Pharmaceuticals, a biotechnology company based in Watertown, Mass., has named Scott McCallister, M.D., as chief medical officer. He is responsible for medical affairs and spearheads the development efforts for bevirimat (PA-457), a new class of oral HIV therapeutics under development.

Before joining Panacos, Dr. McCallister was director of virology, global medical affairs, for Bristol-Myers Squibb. He was responsible for the global medical strategy of the anti-HIV protease inhibitor, atazanavir (Reyataz), and coordinated the review and approval of other virology studies, both internal and external.

Dr. McCallister also has served as associate chief of HIV medicine at the Illinois Masonic Medical Center in Chicago. Dr. McCallister completed his studies at St. George's University School of Medicine and the University of California, Los Angeles.

## Biopharmaceutical POOL

## Dr. Rene BELDER

### Pharmacopeia Appoints VP, Clinical and Regulatory Affairs

Pharmacopeia has named Rene Belder, M.D., to the newly created position of VP, clinical and regulatory affairs.

Pharmacopeia, Cranbury, N.J., is an innovator in the discovery and development of novel small-molecule therapeutics in the areas of clinical development and regulatory affairs.

Dr. Belder joins Pharmacopeia to lead the design and implementation of an efficient clinical development program for dual-acting angiotensin and endothelin receptor antagonist (DARA).

Previously, Dr. Belder spent 19 years at Bristol-Myers Squibb, where he served as a therapeutic expert in the areas of cardiovascular and metabolic diseases.

## Dr. Alan B. COLOWICK

### Geron Appoints President, Oncology

Geron, Menlo Park, Calif., has appointed Alan B. Colowick, M.D., M.P.H., as president, oncology.

Dr. Colowick, 44, is responsible for the operational and strategic activities of the company's oncology programs. Geron is a biopharmaceutical company that is developing and intends to commercialize first-in-class therapeutic products for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes, and HIV/AIDS. Before joining Geron, Dr. Colowick was the chief medical officer of Threshold Pharmaceuticals.

Dr. Colowick was a clinical and research fellow in hematology-oncology at Harvard University and the Dana Farber Cancer Institute. He earned his M.P.H. at the Harvard School of Public Health and his M.D. at Stanford University School of Medicine.

## Dr. James GILBERT

### Archemix Strengthens Management

Archemix, a privately held biopharmaceutical company based in Cambridge, Mass., has appointed James Gilbert, M.D., as chief medical officer and senior VP of clinical and regulatory affairs.

He is responsible for clinical strategies and



priorities, and the design and implementation of clinical trials of aptamer therapeutics, as well as for regulatory affairs and interaction with the FDA. Before joining Archemix, Dr. Gilbert was VP of clinical develop-

ment, cardiovascular/inflammation, at Millennium Pharmaceuticals.

He received his doctor of medicine from the University of Connecticut School of Medicine and his bachelor's degree from Yale University in Molecular Biophysics and Biochemistry.

## Carl F. GROVE

## Dr. John Anthony HEY

### Athenagen Expands Leadership Team

Athenagen has named Carl F. Grove, VP of development operations, and John Anthony Hey, Ph.D., VP of nonclinical development. Athenagen, South San Francisco, Calif., is a privately held biopharmaceutical company focused on neurovascular diseases.

Mr. Grove joins Athenagen from Sequus (now part of Alza and Johnson & Johnson), where for 13 years he held a variety of positions, including VP of regulatory affairs.

He holds B.S. and M.S. degrees in urban planning from California State University, San Luis Obispo, and the University of Oregon in Eugene, respectively.

Dr. Hey is responsible for the research and preclinical development of Athenagen's Oklahoma City-based scientific teams, as well as taking the role as group leader of the company's beta-secretase inhibitor program. He received his Ph.D. in pharmacology from the University of Oklahoma Health Sciences Center and completed postdoctoral training at the Dean McGee Eye Institute at the University of Oklahoma.

## Irwin LERNER

### Medarex names Interim President and CEO

Irwin Lerner, chairman of the Medarex board of directors since 1997, has been named interim president and CEO. Mr. Lerner is the former chairman of the board and CEO of Hoffmann-La Roche.

Medarex, Princeton, N.J., is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapies

to treat life-threatening and debilitating diseases.

Mr. Lerner succeeds Donald L. Drakeman.

He received a B.S. and an MBA from Rutgers University. He is currently a distinguished executive-in-residence at Rutgers University Business School.

## David D. MUTH

### Avalon Names Executive VP, Chief Business Officer

Avalon Pharmaceuticals, Germantown, Md., a biopharmaceutical company focused on the discovery and development of small-molecule therapeutics, has appointed David D. Muth to the newly created position of executive VP, chief business officer.

Mr. Muth contributes to the development of the corporate strategy, is responsible for new commercial opportunities, and directs all business development activities.

Most recently, Mr. Muth served as president and CEO of Osmotica Pharmaceutical, where he built a CNS pipeline.

Mr. Muth received a B.S. in accounting from Villanova University, an MBA in finance from Pace University, and an MBA in pharmaceutical marketing from Farleigh Dickinson University.

## Dr. Peter POWCHIK

### Regeneron Names Senior VP, Clinical Development

Regeneron Pharmaceuticals, a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions, has appointed Peter Powchik, M.D., senior VP of clinical development.

Dr. Powchik has played a key role at major pharmaceutical companies in guiding important products successfully through the clinical and regulatory process.

Dr. Powchik joins Regeneron, Tarrytown, N.Y., from Chugai Pharma, where he was senior VP and chief medical officer.

Dr. Powchik received an M.D. from the New York University School of Medicine.

## Gary J. STERNBERG

### Fovea Selects Senior VP and Chief Business Officer

Fovea Pharmaceuticals, a Paris-based biopharmaceutical company specializing in the discovery, development, and commercialization of innovative drugs for the treatment of ocular dis-

eases, with special focus on retinal pathologies, has appointed Gary J. Sternberg, M.D., MBA, to senior VP and chief business officer.

Dr. Sternberg is based at the New York office and focuses on licensing and product acquisition strategy. He also will assist Fovea to develop and market therapies directed at diseases in the ophthalmic space. Dr. Sternberg has more than 12 years of experience in licensing, business development, clinical research, and medical practice. Most recently, he was VP of alliance management and business development at Eyetech Pharmaceuticals.

## Dr. Paul STRAUSS

### Omeros Names VP, Clinical Development



Omeros, Seattle, has named Paul Strauss, M.D., as VP of clinical development. Omeros is a biopharmaceutical company advancing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery, and pain management.

Dr. Strauss is responsible for overseeing and directing all clinical activities at Omeros.

Dr. Strauss received his M.D. from the University of Stellenbosch and his specialist degree from the University of Cape Town.

## Dr. Mark O. THORNTON

### GenVec Names Senior VP, Clinical Development

GenVec, Gaithersburg, Md., a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines, has appointed Mark O. Thornton, M.D., M.P.H., Ph.D., as senior VP, clinical development.

Dr. Thornton, a clinical pharmacologist and trialist, was most recently managing director of clinical and regulatory affairs at Angiotech Pharmaceuticals.

## Dr. John WOMELSDORF

### Cyclacel Pharmaceuticals Names VP, Business Development

Cyclacel Pharmaceuticals, Short Hills, N.J., a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel, mechanism-



targeted drugs to treat human cancers and other serious disorders, has named John Womelsdorf, Ph.D., as VP of business development.

Dr. Womelsdorf has more than 20 years of experience in business development roles, most recently at Johnson & Johnson, where he served as executive director, licensing and new business development, of the pharmaceuticals group.

Dr. Womelsdorf earned his B.S. and his Ph.D. in physical chemistry from Stevens Institute of Technology. He also earned an MBA from Columbia University.

## Joe A. **YOUNG**

### Amylin Pharmaceuticals Appoints Senior VP, Marketing

Amylin Pharmaceuticals, San Diego, a biopharmaceutical company committed to improving lives through the discovery, development, and commercialization of innovative medicines, has named Joe A. Young senior VP of marketing.

Before joining Amylin, Mr. Young was VP of diabetes brand marketing at Novo Nordisk.

As a member of Amylin's senior management team, Mr. Young replaces Dwayne M. Elwood, who continues with Amylin as an executive advisor.

---

## Specialty **POOL**

---

## John D. **ABERNATHY**

## Patrick G. **LEPORE**

### Par Pharmaceutical Names President and CEO, and Nonexecutive Chairman

Par Pharmaceutical, Spring Valley, N.Y., has named John D. Abernathy nonexecutive chairman. Par Pharmaceutical develops, manufactures, and markets generic drugs and innovative branded pharmaceuticals for specialty markets.

Patrick G. LePore has been appointed as president and CEO. He has almost 30 years of experience in the pharmaceutical and health-care industries.

Mr. LePore, 51, earned his bachelor's degree from Villanova University and his MBA at Fairleigh Dickinson University.

## Dr. Ronald **DUNDORE**

### Infacare Appoints VP, Regulatory and Quality Affairs

Infacare Pharmaceutical, a privately held, pediatric-focused specialty pharmaceutical company, has appointed Ronald Dundore, Ph.D., as VP, regulatory and quality affairs. As a member of the management team, he is responsible for setting and implementing regulatory strategy for Infacare.

Dr. Dundore joins Infacare, Plymouth Meeting, Pa., from AstraZeneca, where he was director, U.S. regulatory affairs. He has more than 20 years of experience in the pharmaceutical industry as a regulatory professional and as a research and development scientist.

Dr. Dundore received his Ph.D. in pharmacology from Pennsylvania State University.

## Dr. Penny **HEATON**

### Novavax Names CMO

Novavax, Malvern, Pa., which is focused on creating novel, highly potent vaccines that are safe and more effective than current preventive options, has named Penny Heaton, M.D., to the newly created position of chief medical officer. Dr. Heaton joins the company after a seven-year career at Merck's Research Laboratories, where she served as senior director of vaccines clinical research.

Dr. Heaton is responsible for all medical and regulatory affairs. She leads the clinical development programs for Novavax's pandemic and seasonal influenza vaccines.

A graduate of the University of the Louisville School of Medicine in Kentucky, Dr. Heaton is a member of the Pediatric Infectious Diseases Society and a fellow of the American Academy of Pediatrics.

---

## Drug Delivery **POOL**

---

## Dr. Amy **O'DONNELL**

### Penwest Names Senior Director, Clinical Development

Amy O'Donnell, M.D., has joined Penwest Pharmaceuticals, Danbury, Conn., as senior director, clinical development. Penwest focuses its development efforts principally on products that address disorders of the nervous system.

Dr. O'Donnell is responsible for providing

the medical and scientific leadership. In this capacity, she oversees the planning, execution, and interpretation of clinical trials.

Dr. O'Donnell, 43, is board certified in neurology. Before joining Penwest, she was a director in neuroscience global clinical research at Bristol-Myers Squibb.

Dr. O'Donnell earned a B.A. from Bryn Mawr College, a J.D. from New York University Law School, and an M.D. from Brown University.

---

## Device/Diagnostic **POOL**

---

## Daryl J. **FAULKNER**

### Digene Appoints CEO

Daryl J. Faulkner, 57, has been named president and CEO of Digene, a developer, manufacturer, and marketer of proprietary DNA and RNA testing systems for the screening, monitoring, and diagnosis of human diseases. Mr. Faulkner brings to Digene, Gaithersburg, Md., experience in building and leading large businesses in the life-sciences and medical-device industries. During an eight-year tenure at Invitrogen, he served in several senior-level capacities.

Mr. Faulkner takes over from Evan Jones, who announced in June 2006 his decision to retire as CEO of Digene after 16 years. Mr. Jones continues to serve on the board of directors as nonexecutive chairman.

Mr. Faulkner earned a bachelor's degree in industrial relations from the University of North Carolina and a master's in business management from Webster University in Saint Louis.

---

## Emerging **POOL**

---

## Dr. Richard **HEYMAN**

## Dr. Richard **LAI FATT**

### Kalypsys Appoints Two Executives to Leadership Team

Kalypsys, San Diego, has announced the appointment of Richard Heyman, Ph.D., as senior VP, drug discovery, and Richard Lai Fatt, Ph.D., as VP, corporate development.



Dr. Heyman is responsible for directing the company's drug-discovery efforts, as well as interfacing with new corporate partners. He has more than 16 years of experience in the biotechnology and pharmaceutical industries. Before joining Kalypsys, he was senior VP of metabolic diseases for Exelixis.



Dr. Heyman has held positions with Ligand Pharmaceuticals, where he was responsible for multiple drug discovery programs, including two retinoids that were approved for the treatment of cancer.

He holds a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.

Dr. Lai Fatt focuses on business initiatives and corporate development activities related to Kalypsys' growing drug pipeline. He has extensive business development and new product planning experience in the pharmaceutical industry.

Before joining Kalypsys, he was VP of business development and strategic marketing for Isis Pharmaceuticals. Dr. Lai Fatt holds a Ph.D. in biology from McMaster University and a B.S. in biology from the University of Miami.

## Dr. Graham S. **MAY**

## Bruce **OSTHOFF**

### EKR Therapeutics Expands Management Team

EKR Therapeutics, Cedar Knolls, N.J., an emerging specialty pharmaceutical company, has expanded its management team.

Dr. Graham S. May has been appointed senior VP and chief medical officer, while Bruce Osthoff has been named regional sales director.

Dr. May joins EKR from Esprit Pharma. He has more than 25 years of experience as a pharmaceutical development physician in the drug, medical-device, and biotechnology research industry in the United States and Europe.

Dr. May has an undergraduate degree from Cambridge University and is an Elected Fellow of the Faculty of Pharmaceutical Physicians.

Mr. Osthoff, previously regional sales director of PDL Biopharma, brings demonstrated success in building and managing sales teams.

Mr. Osthoff has a B.S. in mathematics and statistics from the University of Florida.

## David W. **PRITCHARD**

### KaloBios Pharmaceuticals Names President and CEO

KaloBios Pharmaceuticals, Palo Alto, Calif., a privately held biopharmaceutical company, has appointed David W. Pritchard as president and CEO.

Most recently, Mr. Pritchard held the position of chief business officer at Rinat Neuroscience.

Mr. Pritchard holds an MBA from Stanford University and a B.S. in chemical engineering from Cornell.

KaloBios Pharmaceuticals is a therapeutic antibody company using its proprietary antibody engineering, humanizing, and expression technologies for the development of a pipeline of antibody therapeutics.

## Agency **POOL**

## Jon **ANGELLO**

### The Navicor Group Welcomes New Hire

The Navicor Group, Columbus, Ohio, an inVentiv Health company and a full-service advertising agency, welcomes Jon Angello as art director.

Most recently, Mr. Angello served as professional sales representative for Publicis Selling Solutions.

Mr. Angello holds a bachelor of fine arts degree from Indiana University of Pennsylvania.

## Doug **BURCIN**

## Dr. Jim **METROPOULOS**

## Donna **MURPHY**

## Michel **NAKACHE**

## Ron **PANTELLLO**

## Ed **STAPOR**

### New Global Management Team for Euro RSCG Life Worldwide



Euro RSCG Life Worldwide, Washington, D.C., a global healthcare communications network of Euro RSCG World-



wide, has announced several changes and the appointment of a global management team.

Doug Burcin, president, Euro RSCG Life Metamax, assumes the role of co-CEO, North America, for Euro RSCG Life.

Jim Metropoulos, M.D., has been appointed CEO of Euro RSCG Life Worldwide. He joins the company from Sudler & Hennessey, a division of the WPP Group, where he had been co-president.

Ron Pantello moves into the role of chairman, Euro RSCG Life Worldwide, after serving as CEO. He has been with the agency for 26 years.

Ed Stapor, president, Euro RSCG Life Chelsea, joins Mr. Burcin as co-CEO, North America.

The four, along with Donna Murphy, chief operating officer, Euro RSCG Life Worldwide, and Michel Nakache, CEO Europe/Asia, Euro RSCG Life, form the six-member global management team, which delivers cross-market and discipline management to all of Euro RSCG Life Worldwide's 44 offices in 22 countries.



## Michael **DEPIRRO**

## Lisa **GARRONE**

## Michael **O'LAUGHLIN**

## Kristen **PHIEL**

## Matthew **SISLOWITZ**

### GSW Worldwide Announces New Hires

GSW Worldwide, Columbus, Ohio, an inVentiv Health company and one of the largest healthcare advertising agencies in the world, has hired Michael DePirro and Lisa Garrone, former senior VP/group creative directors at Deutsch, to lead the creative department in the company's New York office.

Michael O'Laughlin joins GSW's Pennsylvania office as VP, account director. He comes to GSW Worldwide with more than 15 years of marketing experience.

Most recently, he served as senior manager, healthcare promotion, at AstraZeneca with responsibilities for the professional marketing of Seroquel. He holds a bachelor's degree from Benedictine University and an MBA from Widener University.

GSW Worldwide recently welcomed Kristen Phiel to its Columbus, Ohio, office. Ms. Phiel was named medical marketing writer with responsibility for combining the creative vision, the medical data, and the brand strategy for assigned accounts.

Most recently, Ms. Phiel served as scientific coordinator and writer for Columbus Children's Hospital Research Institute. Ms. Phiel holds a bachelor's degree from Ursinus College and a master's degree from Temple University.

Matthew Sislowitz has been appointed to GSW Worldwide's New York office as a senior copywriter.

Most recently, Mr. Sislowitz served as copywriter for Grey Healthcare. He holds a bachelor's degree from Brown University.

Angela **ESCUDERO**

Trish **HEINFELDT**

#### Stonefly Promotes Art Supervisor

Stonefly Communications Group, Columbus, Ohio, a customer-centric healthcare advertising agency and an inVentiv Health company, has promoted Trish Heinfeldt to art supervisor.

Ms. Heinfeldt joined Stonefly in 2004. Previously, she served as group art supervisor for GSW Worldwide, another inVentiv Health company, where she was responsible for developing the visual orientation and design for designated projects.

She holds a bachelor's degree from Bowling Green State University.

Laura **HAYES**

Carolyn **MAHONEY**

Leigh **RENER**

Collie **TURNER**

Caroline **YOON**

#### Growth Prompts New Hires at imc<sup>2</sup>

In response to new growth, imc<sup>2</sup>, an independent digital marketing agency with offices in Dallas, New York, Philadelphia, and Cincinnati, has added five employees to its Philadelphia office.

New hires for the Philadelphia office include: Laura Hayes, senior project manager; Carolyn Mahoney, senior project manager; Leigh Renfer, project manager; Collie Turner, account manager, and Caroline Yoon, senior account executive.

Lisa **KAUFMAN**

Kelli **MCKENNA**

Amanda **SANTISE**

#### Additional Staff for Centron

Centron, N.Y., a full-service medical communications agency and part of the HealthSTAR Communications network, has announced the appointment of additional staff.

Lisa Kaufman joins as account supervisor. Before joining Centron, Ms. Kaufman was a senior account executive at Grey Healthcare Group.

Kelli McKenna, M.S., joins Centron as senior account executive. She was most recently an account executive at Phase Five Communications.

Amanda Santise comes to Centron as medical communications team coordinator. Before joining Centron, Ms. Santise was a marketing and public relations coordinator at Orange Regional Medical Center.

Laurence **MORAN**

#### CommonHealth Promotes IT Leader

CommonHealth, Parsippany, N.J., a WPP Group company and healthcare-communications network, has promoted Laurence Moran to executive VP, chief information officer.

In his new role, Mr. Moran is responsible for overseeing the CommonHealth network's information technology policies, procedures, and initiatives.

Mr. Moran joined the CommonHealth network almost three years ago.

#### Consulting **POOL**

Raymond T. **OJI**

#### Parexel Consulting Expands Risk Management Expertise

Parexel Consulting, a global life-sciences consultancy and division of Parexel Interna-

tional, has expanded its risk management and strategic compliance expertise with the appointment of Raymond T. Oji to the position of senior consultant. Formerly a microbiologist and consumer safety officer in the U.S. Food and Drug Administration San Francisco District, Mr. Oji brings 40 years of experience in performing pharmaceutical inspections and drug and device analyses to Parexel Consulting, Lowell, Mass.

#### CRO **POOL**

Dr. Sylva H. **COLLINS**

#### Kendle Appoints VP, Global Biometrics

Kendle, Cincinnati, a global CRO, has appointed Sylva H. Collins, Ph.D., as VP, global biometrics. In addition to her scientific and management expertise, Dr. Collins is a recognized thought leader in the electronic data capture field.

Dr. Collins was previously a VP in Novartis' global advanced clinical systems, and VP, global electronic data management.

Dr. Kevin L. **KEIM**

#### INC Research Appoints Chief Development Officer

Kevin L. Keim, Ph.D., M.Sc., has been appointed chief development officer for INC Research, Raleigh, N.C., a therapeutically focused CRO.

Dr. Keim is responsible for INC's new outreach program to the Japanese pharmaceutical and biotechnology business communities.

His experience includes global business development, marketing and communications, regulatory services (including safety and pharmacovigilance), early clinical-phase product development services, and the pediatrics division.

Dr. Keim is a trained pharmacologist, and brings more than 39 years of research and discovery, clinical research, and regulatory experience to INC Research.

Most recently, Dr. Keim has served as president and CEO and board director of Vela Pharmaceuticals, as well as founder and managing principal of K.L. Keim Consulting Group.

Dr. Keim received his doctoral degree from New York University and his master's of science degree from Fairleigh Dickinson Univer-



sity. His undergraduate work was done at Delaware Valley College.

## David E. **WILLIAMS**

### Clinsys Appoints CEO, Worldwide Operations

David E. Williams, CPA, CMA, MBA, has been named CEO of Clinsys' worldwide operations. Clinsys, Berkeley Heights, N.J., and New Delhi, India, is a global provider of clinical research and data management.

Mr. Williams has more than 25 years of experience in the pharmaceutical and biotechnology industries.

He spent the past six years with INC Research, where he served most recently as president and chief financial officer.

He leads a team of dedicated staff in the United States and India.

## Contact Sales **POOL**

## David N. **STIEVATER**

### PDI Appoints Senior VP, Emerging Pharma

David N. Stievater has joined PDI, Saddle River N.J., in the newly created position of senior VP, emerging pharma. Mr. Stievater joins PDI, a contract sales and marketing services provider, from ImpactRx, where he served as VP, sales, and VP, business development.

Mr. Stievater earned his MBA from the University of Michigan and a B.S. from Georgetown University.

## Medical-Education **POOL**

## Jessica **DIPAOLLO**

## Jennifer **O'BRIEN**

### HealthEd Adds Staff to Meet Growth Needs

HealthEd, Clark, N.J., a patient-education marketing company, has named Jessica DiPaolo as manager, strategic services. In this role, she liaises with the firm's business devel-

opment team, and she is responsible for needs assessments and market research analysis to better understand patient barriers and motivators.

Before joining HealthEd, Ms. DiPaolo worked as an independent healthcare consultant.

Jennifer O'Brien has joined HealthEd as VP, account supervisor. She is responsible for management and growth of a variety of pharmaceutical brand accounts. She oversees the integration of the skills of health educators, strategists, and creative designers to develop effective patient education programs.

An industry veteran, Ms. O'Brien brings significant marketing expertise and insight from corporate and agency practices.

Before joining HealthEd, Ms. O'Brien was a VP and account supervisor at DVC Worldwide.

## Service **POOL**

## Barry **BURNSTEAD**

### i3 Statprobe Hires Project Management Director

Pharmaceutical services company, i3, Ann Arbor, Mich., an Ingenix company, has appointed Barry Burnstead as director of project management for i3 Statprobe's European business.

Mr. Burnstead brings a wealth of experience in project management, at the drug development level, to the position.

He is a member of the European CDISC coordinating committee (E3C), a standards-setting organization in clinical research.

He comes to i3 from Phase Forward, where he held a series of international positions, including head of global program management.

## Dr. James J. **VORNOV**

### Parexel Appoints Neuroscience Expert to Senior Medical Director

James J. Vornov, M.D., Ph.D., an internationally recognized neuroscience and drug-development expert, has joined Parexel's clinical-research services group as a senior medical director. Dr. Vornov acts as clinical practice leader and provides consultation to clients sponsoring clinical trials in the central nervous system therapy area.

Dr. Vornov's provision of medical insight to clients throughout the clinical development

continuum ranges from the development of clinical plans and design of protocols to the conduct of trials.

Parexel International, Waltham, Mass., is a global bio/pharmaceutical services organization.

Before joining Parexel, Dr. Vornov was senior medical director of experimental medicine at MGI Pharma.

He holds M.D. and Ph.D. degrees from the Emory School of Medicine and completed his residency training at Johns Hopkins School of Medicine. He is board certified in neurology.

## Pardon Us...

In the October 2006 issue, we inadvertently depicted several prominent industry personalities with the wrong photo. We apologize for any inconvenience or confusion these errors caused.



Dr. Sidney **MAZEL**

Senior VP, product planning and portfolio management  
**MedImmune**



Cecil B. **PICKETT**, Ph.D.

President of research and development  
**Biogen Idec**



J. Michael **HAMILTON**, M.D.

Chief Medical Officer  
**Avalon Pharmaceuticals**



Charles P. **THEUER**, M.D., Ph.D.

President and CEO  
**Tracon Pharmaceuticals**



Meg **COLUMBIA-WALSH**

Managing Partner and President  
**CommonHealth**